Smruthi Organics has reported results for first quarter ended June 30, 2018.
The company has reported net profit of Rs 2.19 crore for the quarter under review as against a net loss Rs 0.14 crore for the same quarter in the previous year. Total revenue from operations of the company increased by 64.32% at Rs 28.97 crore for Q1FY19 as compared Rs 17.63 crore for the corresponding quarter previous year.
Smruthi Organics’ core competency is multi-step organic synthesis and large scale manufacturing of organic molecules.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: